Peptidoglycan D,D-transpeptidase FtsI · SINGLE PROTEIN · Escherichia coli
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Peptidoglycan D,D-transpeptidase FtsI shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt C3TQQ7. Start with bacterial disease, then reuse UniProt C3TQQ7 as the stable protein anchor across project notes and exports.
Start with bacterial disease, then reuse UniProt C3TQQ7 as the stable protein anchor across project notes and exports.
Peptidoglycan D,D-transpeptidase FtsI shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include ERTAPENEM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPeptidoglycan D,D-transpeptidase FtsI
Review this target as Peptidoglycan D,D-transpeptidase FtsI, mapped to UniProt C3TQQ7. Sequence length is 588 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peptidoglycan D,D-transpeptidase FtsI as ChEMBL target CHEMBL5500282, mapped to UniProt C3TQQ7. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Peptidoglycan D,D-transpeptidase FtsI is the right protein anchor across sources, using UniProt C3TQQ7 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why bacterial disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Peptidoglycan D,D-transpeptidase FtsI |
| Target Type | SINGLE PROTEIN |
| Organism | Escherichia coli |
| UniProt | C3TQQ7 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Peptidoglycan D,D-transpeptidase FtsI |
| UniProt Accession | C3TQQ7 |
| Component Type | Protein |
| Sequence Length | 588 aa |
Peptidoglycan D,D-transpeptidase FtsI
Review this target as Peptidoglycan D,D-transpeptidase FtsI, mapped to UniProt C3TQQ7. Sequence length is 588 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Peptidoglycan D,D-transpeptidase FtsI shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include ERTAPENEM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.